FDA panel gives both barrels to Spectrum and Oncopeptides

21 September 2022

Shares in US biopharma Spectrum Pharmaceuticals (Nasdaq: SPPI) dropped by a massive 37% on Tuesday while those in Swedish biotech Oncopeptides (STO: ONCO) closed 25% lower.

Both companies’ products had been on the receiving end of damning US Food and Drug Administration (FDA) briefing documents ahead of this week’s meeting of the agency’s Oncologic Drugs Advisory Committee, which takes place on Thursday and Friday.

Concerns over evidence submitted

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK